[424B5] Predictive Oncology Inc. Prospectus Supplement (Debt Securities)
Predictive Oncology (POAI) filed a prospectus supplement for an at-the-market offering of up to $18,330,000 of common stock under its agreement with H.C. Wainwright, subject to General Instruction I.B.6 limits.
Over the last 12 months, the company sold 139,680 shares for aggregate gross proceeds of approximately $1,872,333 through the ATM. As calculated within 60 days of this supplement, public float was $62,257,699, based on 3,458,934 non‑affiliate shares at $17.9991. The company noted $2,417,337 of securities sold pursuant to I.B.6 in the same period. If public float rises above $75.0 million, the I.B.6 cap would no longer apply; additional capacity would be reflected in a future supplement.
As of October 28, 2025, the company held approximately 5.49 billion Aethir tokens valued at about $159.2 million based on a $0.0290 price.
Predictive Oncology (POAI) ha depositato un supplemento al prospetto per un'offerta sul mercato aperto di fino a $18,330,000 di azioni ordinarie nell'ambito del suo accordo con H.C. Wainwright, soggetto ai limiti dell'Istruzione Generale I.B.6.
Negli ultimi 12 mesi, la società ha venduto 139,680 azioni per introiti lordi complessivi di circa $1,872,333 tramite l'ATM. Calcolando entro 60 giorni da questo supplemento, il flottante pubblico era di $62,257,699, basato su 3,458,934 azioni non affiliate a $17.9991. La società ha inoltre osservato $2,417,337 di titoli venduti ai sensi di I.B.6 nello stesso periodo. Se il flottante pubblico dovesse superare $75,0 milioni, il limite I.B.6 non si applicherebbe; ulteriore capacità verrebbe riflessa in un futuro supplemento.
Al 28 ottobre 2025, la società deteneva circa 5,49 miliardi di token Aethir valutati a circa $159,2 milioni in base a un prezzo di $0,0290.
Predictive Oncology (POAI) presentó un suplemento al prospecto para una oferta en el mercado de hasta $18,330,000 de acciones ordinarias conforme a su acuerdo con H.C. Wainwright, sujeto a los límites de la Instrucción General I.B.6.
En los últimos 12 meses, la empresa vendió 139,680 acciones por ingresos brutos agregados de aproximadamente $1,872,333 a través del ATM. Calculando dentro de los 60 días de este suplemento, el flottante público era de $62,257,699, basado en 3,458,934 acciones no afiliadas a $17.9991. La empresa señaló $2,417,337 de valores vendidos conforme a I.B.6 en el mismo periodo. Si el flotante público aumenta por encima de $75.0 millones, el tope I.B.6 ya no se aplicaría; la capacidad adicional se reflejaría en un suplemento futuro.
A 28 de octubre de 2025, la empresa poseía aproximadamente 5.49 mil millones de tokens Aethir valorados en aproximadamente $159.2 millones basados en un precio de $0.0290.
Predictive Oncology (POAI)은 H.C. Wainwright와의 계약에 따라 일반 주식의 시장공모 형태로 최대 $18,330,000의 주식을 위한 프루스펙스 보충서를 제출했습니다. 이는 일반 지침 I.B.6의 한도에 따릅니다.
지난 12개월 동안 회사는 ATM을 통해 총 139,680주를 매출액 총계 약 $1,872,333의 gross-proceeds로 팔았습니다. 이 보충서의 60일 이내에 계산한 공개 시가총액은 $62,257,699였으며, $17.9991의 가격으로 3,458,934주의 비계열주식에 근거합니다. 회사는 같은 기간에 I.B.6에 따라 $2,417,337의 증권이 판매되었다고 밝혔습니다. 공개 시가총액이 $75.0 million을 초과하면 I.B.6 한도가 더 이상 적용되지 않으며, 추가 용량은 향후 보충서에 반영됩니다.
2025년 10월 28일 기준으로 회사는 약 5.49십억 개의 Aethir 토큰을 보유하고 있으며 가격은 $0.0290로 평가되어 약 $159.2 million입니다.
Predictive Oncology (POAI) a déposé un supplément de prospectus pour une offre au marché allant jusqu'à $18,330,000 de actions ordinaires en vertu de son accord avec H.C. Wainwright, sous réserve des limites de l'Instruction Générale I.B.6.
Au cours des 12 derniers mois, la société a vendu 139,680 actions pour des produits bruts agrégés d'environ $1,872,333 par le biais de l'ATM. Calculé dans les 60 jours suivant ce supplément, le flottant public était de $62,257,699, basé sur 3,458,934 actions non affiliées à $17.9991. La société a noté $2,417,337 de valeurs vendues conformément à l'I.B.6 au cours de la même période. Si le flottant public dépasse $75,0 millions, la limite I.B.6 ne s'appliquerait plus; une capacité supplémentaire serait reflétée dans un futur supplément.
Au 28 octobre 2025, la société détenait environ 5,49 milliards de jetons Aethir évalués à environ $159,2 millions sur la base d'un prix de $0,0290.
Predictive Oncology (POAI) hat eine Prospektzusatz für ein Offerten am Markt in Höhe von bis zu $18,330,000 Aktien gemäß seiner Vereinbarung mit H.C. Wainwright eingereicht, vorbehaltlich der Begrenzungen der allgemeinen Anweisung I.B.6.
In den letzten 12 Monaten verkaufte das Unternehmen 139,680 Aktien für Bruttoerlöse von ca. $1,872,333 über das ATM. Berechnet innerhalb von 60 Tagen nach diesem Zusatz betrug der öffentliche Streubesitz $62,257,699, basierend auf 3,458,934 nicht-verbundene Aktien zu $17.9991. Das Unternehmen vermerkte $2,417,337 an Wertpapieren, die gemäß I.B.6 im gleichen Zeitraum verkauft wurden. Wenn der öffentliche Streubesitz $75,0 Millionen überschreitet, gilt die I.B.6-Obergrenze nicht mehr; zusätzliche Kapazität würde in einer zukünftigen Ergänzung reflektiert.
Zum 28. Oktober 2025 hielt das Unternehmen ca. 5,49 Milliarden Aethir-Token im Wert von ca. $159,2 Millionen basierend auf einem Preis von $0,0290.
Predictive Oncology (POAI) قدمت ملاحظة في نشرة إصدار لإجراء عرض في السوق حتى يصل إلى $18,330,000 من الأسهم العادية وفقاً لاتفاقها مع H.C. Wainwright، رهناً بقيود التعليمات العامة I.B.6.
خلال آخر 12 شهراً، باعت الشركة 139,680 سهماً لإيرادات إجمالية إجمالية تبلغ نحو $1,872,333 من خلال ATM. كما تم حسابه خلال 60 يوماً من هذا الملحق، كان الطفو العام $62,257,699، بناءً على 3,458,934 سهماً غير تابع بسعر $17.9991. أشارت الشركة إلى $2,417,337 من الأوراق المالية المباعة وفقاً لـ I.B.6 في نفس الفترة. إذا ارتفع الطفو العام فوق $75.0 مليون، فلن تنطبق سقف I.B.6؛ ستنعكس القدرة الإضافية في ملاحظة مستقبلية.
اعتباراً من 28 أكتوبر 2025، كانت الشركة تمتلك حوالي 5.49 مليار من رموز Aethir قيمتها نحو $159.2 مليون استناداً إلى سعر قدره $0.0290.
- None.
- None.
Predictive Oncology (POAI) ha depositato un supplemento al prospetto per un'offerta sul mercato aperto di fino a $18,330,000 di azioni ordinarie nell'ambito del suo accordo con H.C. Wainwright, soggetto ai limiti dell'Istruzione Generale I.B.6.
Negli ultimi 12 mesi, la società ha venduto 139,680 azioni per introiti lordi complessivi di circa $1,872,333 tramite l'ATM. Calcolando entro 60 giorni da questo supplemento, il flottante pubblico era di $62,257,699, basato su 3,458,934 azioni non affiliate a $17.9991. La società ha inoltre osservato $2,417,337 di titoli venduti ai sensi di I.B.6 nello stesso periodo. Se il flottante pubblico dovesse superare $75,0 milioni, il limite I.B.6 non si applicherebbe; ulteriore capacità verrebbe riflessa in un futuro supplemento.
Al 28 ottobre 2025, la società deteneva circa 5,49 miliardi di token Aethir valutati a circa $159,2 milioni in base a un prezzo di $0,0290.
Predictive Oncology (POAI) presentó un suplemento al prospecto para una oferta en el mercado de hasta $18,330,000 de acciones ordinarias conforme a su acuerdo con H.C. Wainwright, sujeto a los límites de la Instrucción General I.B.6.
En los últimos 12 meses, la empresa vendió 139,680 acciones por ingresos brutos agregados de aproximadamente $1,872,333 a través del ATM. Calculando dentro de los 60 días de este suplemento, el flottante público era de $62,257,699, basado en 3,458,934 acciones no afiliadas a $17.9991. La empresa señaló $2,417,337 de valores vendidos conforme a I.B.6 en el mismo periodo. Si el flotante público aumenta por encima de $75.0 millones, el tope I.B.6 ya no se aplicaría; la capacidad adicional se reflejaría en un suplemento futuro.
A 28 de octubre de 2025, la empresa poseía aproximadamente 5.49 mil millones de tokens Aethir valorados en aproximadamente $159.2 millones basados en un precio de $0.0290.
Predictive Oncology (POAI)은 H.C. Wainwright와의 계약에 따라 일반 주식의 시장공모 형태로 최대 $18,330,000의 주식을 위한 프루스펙스 보충서를 제출했습니다. 이는 일반 지침 I.B.6의 한도에 따릅니다.
지난 12개월 동안 회사는 ATM을 통해 총 139,680주를 매출액 총계 약 $1,872,333의 gross-proceeds로 팔았습니다. 이 보충서의 60일 이내에 계산한 공개 시가총액은 $62,257,699였으며, $17.9991의 가격으로 3,458,934주의 비계열주식에 근거합니다. 회사는 같은 기간에 I.B.6에 따라 $2,417,337의 증권이 판매되었다고 밝혔습니다. 공개 시가총액이 $75.0 million을 초과하면 I.B.6 한도가 더 이상 적용되지 않으며, 추가 용량은 향후 보충서에 반영됩니다.
2025년 10월 28일 기준으로 회사는 약 5.49십억 개의 Aethir 토큰을 보유하고 있으며 가격은 $0.0290로 평가되어 약 $159.2 million입니다.
Predictive Oncology (POAI) a déposé un supplément de prospectus pour une offre au marché allant jusqu'à $18,330,000 de actions ordinaires en vertu de son accord avec H.C. Wainwright, sous réserve des limites de l'Instruction Générale I.B.6.
Au cours des 12 derniers mois, la société a vendu 139,680 actions pour des produits bruts agrégés d'environ $1,872,333 par le biais de l'ATM. Calculé dans les 60 jours suivant ce supplément, le flottant public était de $62,257,699, basé sur 3,458,934 actions non affiliées à $17.9991. La société a noté $2,417,337 de valeurs vendues conformément à l'I.B.6 au cours de la même période. Si le flottant public dépasse $75,0 millions, la limite I.B.6 ne s'appliquerait plus; une capacité supplémentaire serait reflétée dans un futur supplément.
Au 28 octobre 2025, la société détenait environ 5,49 milliards de jetons Aethir évalués à environ $159,2 millions sur la base d'un prix de $0,0290.
Predictive Oncology (POAI) hat eine Prospektzusatz für ein Offerten am Markt in Höhe von bis zu $18,330,000 Aktien gemäß seiner Vereinbarung mit H.C. Wainwright eingereicht, vorbehaltlich der Begrenzungen der allgemeinen Anweisung I.B.6.
In den letzten 12 Monaten verkaufte das Unternehmen 139,680 Aktien für Bruttoerlöse von ca. $1,872,333 über das ATM. Berechnet innerhalb von 60 Tagen nach diesem Zusatz betrug der öffentliche Streubesitz $62,257,699, basierend auf 3,458,934 nicht-verbundene Aktien zu $17.9991. Das Unternehmen vermerkte $2,417,337 an Wertpapieren, die gemäß I.B.6 im gleichen Zeitraum verkauft wurden. Wenn der öffentliche Streubesitz $75,0 Millionen überschreitet, gilt die I.B.6-Obergrenze nicht mehr; zusätzliche Kapazität würde in einer zukünftigen Ergänzung reflektiert.
Zum 28. Oktober 2025 hielt das Unternehmen ca. 5,49 Milliarden Aethir-Token im Wert von ca. $159,2 Millionen basierend auf einem Preis von $0,0290.
Predictive Oncology (POAI) قدمت ملاحظة في نشرة إصدار لإجراء عرض في السوق حتى يصل إلى $18,330,000 من الأسهم العادية وفقاً لاتفاقها مع H.C. Wainwright، رهناً بقيود التعليمات العامة I.B.6.
خلال آخر 12 شهراً، باعت الشركة 139,680 سهماً لإيرادات إجمالية إجمالية تبلغ نحو $1,872,333 من خلال ATM. كما تم حسابه خلال 60 يوماً من هذا الملحق، كان الطفو العام $62,257,699، بناءً على 3,458,934 سهماً غير تابع بسعر $17.9991. أشارت الشركة إلى $2,417,337 من الأوراق المالية المباعة وفقاً لـ I.B.6 في نفس الفترة. إذا ارتفع الطفو العام فوق $75.0 مليون، فلن تنطبق سقف I.B.6؛ ستنعكس القدرة الإضافية في ملاحظة مستقبلية.
اعتباراً من 28 أكتوبر 2025، كانت الشركة تمتلك حوالي 5.49 مليار من رموز Aethir قيمتها نحو $159.2 مليون استناداً إلى سعر قدره $0.0290.
As Filed Pursuant to Rule 424(b)(5)
Registration No. 333-279123
PROSPECTUS SUPPLEMENT
(To Prospectus dated May 21, 2024 and the Prospectus Supplements dated May 21, 2024, April 18, 2025, and June 2, 2025)
Up to $18,330,000
Common Stock
This prospectus supplement (this “Prospectus Supplement”) amends and supplements certain information in the prospectus, dated May 21, 2024, filed with the Securities and Exchange Commission (the “SEC”) as part of our registration statement on Form S-3 (333-279123), as supplemented by our prospectus supplement, dated May 21, 2024, as further supplemented by the prospectus supplements dated April 18, 2025 and June 2, 2025 (collectively with this Prospectus Supplement, the “ATM Prospectus”), relating to the offer and sale of shares of our common stock, par value $0.01 per share (“Common Stock”), from time to time pursuant to the terms of the certain ATM Sales Agreement, dated May 3, 2024 (the “Agreement”), we entered into with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent. During the twelve calendar months prior to, and including, the date hereof, we have sold an aggregate of 139,680 shares of our Common Stock, as adjusted to reflect the one-for-fifteen reverse stock split effected on September 29, 2025, for aggregate gross proceeds of approximately $1,872,333 through Wainwright under the Agreement. This Prospectus Supplement should be read in conjunction with the ATM Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the ATM Prospectus, and any future amendments or supplements thereto.
As of a date within 60 days of this Prospectus Supplement, the aggregate market value of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $62,257,699, which was calculated based on 3,458,934 shares of our outstanding Common Stock held by non-affiliates and a price of $17.9991 per share, the closing price of our Common Stock on September 29, 2025, which is the highest closing sale price of our Common Stock on the Nasdaq Capital Market within the prior 60 days. As of the date of this Prospectus Supplement, we have sold securities with an aggregate market value of approximately $2,417,337 pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of this Prospectus Supplement. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary offerings on Form S-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.6) in any 12-calendar month period so long as our public float remains below $75.0 million.
We are filing this Prospectus Supplement to amend the ATM Prospectus to update the maximum amount of shares that we are eligible to sell from and after the date hereof, and to specify the value of Common Stock we would be permitted to sell in any 12-calendar month period under General Instruction I.B.6. We may currently only offer and sell shares of our Common Stock having an aggregate offering price of up to $18,330,000 pursuant to this Prospectus Supplement in accordance with the terms of the Agreement, and as a result of the limitations set forth in General Instruction I.B.6. However, in the event that our public float increases or decreases, we may sell securities in public primary offerings on Form S-3 with a value up to one-third of our public float, in each case calculated pursuant to General Instruction I.B.6 and subject to the terms of the Agreement. In the event that our public float increases above $75.0 million, we will no longer be subject to the limits in General Instruction I.B.6 of Form S-3. If our public float increases such that we may sell additional amounts under the Agreement and the registration statement of which this Prospectus Supplement and the ATM Prospectus are a part, we will file another prospectus supplement prior to making additional sales.
On October 28, 2025, the Company held approximately 5.49 billion Aethir tokens (“ATH”), with a market value of approximately $159.2 million, based on a price of $0.0290 per ATH, the price reported on the Coinbase exchange as of 4:00 p.m. ET on such date.
Our Common Stock trades on the Nasdaq Capital Market (“Nasdaq”) under the symbol “POAI.” On October 28, 2025, the last reported sale price of our Common Stock on Nasdaq was $9.69 per share.
INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE “RISK FACTORS” ON PAGE S-9 OF THE ATM PROSPECTUS AND IN THE DOCUMENTS INCORPORATED BY REFERENCE IN THE REGISTRATION STATEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR COMMON STOCK.
Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this Prospectus Supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
H.C. Wainwright & Co.
The date of this Prospectus Supplement is October 29, 2025.
FAQ
What did POAI file in this 424B5 supplement?
How much has POAI sold through the ATM in the past year?
What is POAI’s current public float used for I.B.6?
How much has POAI sold under I.B.6 in the last 12 months?
When do I.B.6 limits cease to apply?
Who is the ATM sales agent?
What digital asset holdings were disclosed?
